ResMed vs Baxter International: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

ResMed Inc (RMD)

Q3 20267 Jul – 15 Sep 2026

▼3▲1

ResMed's growth slows as margins shrink and ventilator recall bites

Margin squeeze hits profits ResMed's operating margin fell to 30.7% from 33.7% a year earlier, and free cash flow margin dropped sharply. Higher research, supply chain and marketing costs, plus a $42 million safety charge, mean the company keeps less profit from each sale, which pushed shares down.
Margin decline is the core reason the stock dropped after earnings and is a key concern for future profitability.
Ventilator recall cuts sales ResMed suspended sales of its Astral ventilators after a serious safety recall. This removes about $75 million of expected revenue in fiscal 2027 and is a main reason the company's revenue forecast came in below what analysts expected, weighing on the stock.
The recall is a concrete, quantified headwind that directly explains the softer guidance and negative price reaction.
Soft FY27 guidance disappoints ResMed guided fiscal 2027 revenue to $5.75–$5.85 billion, below the $5.92 billion consensus. The shortfall, blamed on the ventilator recall and macro uncertainty like inflation in components and freight, caused a 7% share drop as investors worried about slower growth.
Guidance below expectations is a direct driver of the negative stock reaction and sets the growth outlook.
Divestiture and buybacks support focus ResMed is selling its MatrixCare software unit to Frazier Healthcare and buying Noctrix to expand into restless legs syndrome. It also raised its dividend 10% and plans over $1.85 billion in shareholder returns, including a $450 million accelerated share repurchase, signaling confidence and sharper focus on core sleep and respiratory care.
These capital actions show management's efforts to streamline and return cash, offering a positive counterweight to the margin and recall issues.

August 20267 Jul – 15 Sep 2026

▼3▲1

ResMed's growth slows as margins shrink and ventilator recall bites

Margin squeeze hits profits ResMed's operating margin fell to 30.7% from 33.7% a year earlier, and free cash flow margin dropped sharply. Higher research, supply chain and marketing costs, plus a $42 million safety charge, mean the company keeps less profit from each sale, which pushed shares down.
Margin decline is the core reason the stock dropped after earnings and is a key concern for future profitability.
Ventilator recall cuts sales ResMed suspended sales of its Astral ventilators after a serious safety recall. This removes about $75 million of expected revenue in fiscal 2027 and is a main reason the company's revenue forecast came in below what analysts expected, weighing on the stock.
The recall is a concrete, quantified headwind that directly explains the softer guidance and negative price reaction.
Soft FY27 guidance disappoints ResMed guided fiscal 2027 revenue to $5.75–$5.85 billion, below the $5.92 billion consensus. The shortfall, blamed on the ventilator recall and macro uncertainty like inflation in components and freight, caused a 7% share drop as investors worried about slower growth.
Guidance below expectations is a direct driver of the negative stock reaction and sets the growth outlook.
Divestiture and buybacks support focus ResMed is selling its MatrixCare software unit to Frazier Healthcare and buying Noctrix to expand into restless legs syndrome. It also raised its dividend 10% and plans over $1.85 billion in shareholder returns, including a $450 million accelerated share repurchase, signaling confidence and sharper focus on core sleep and respiratory care.
These capital actions show management's efforts to streamline and return cash, offering a positive counterweight to the margin and recall issues.

Latest7 Jul – 15 Sep 2026

▼3▲1

ResMed's growth slows as margins shrink and ventilator recall bites

Margin squeeze hits profits ResMed's operating margin fell to 30.7% from 33.7% a year earlier, and free cash flow margin dropped sharply. Higher research, supply chain and marketing costs, plus a $42 million safety charge, mean the company keeps less profit from each sale, which pushed shares down.
Margin decline is the core reason the stock dropped after earnings and is a key concern for future profitability.
Ventilator recall cuts sales ResMed suspended sales of its Astral ventilators after a serious safety recall. This removes about $75 million of expected revenue in fiscal 2027 and is a main reason the company's revenue forecast came in below what analysts expected, weighing on the stock.
The recall is a concrete, quantified headwind that directly explains the softer guidance and negative price reaction.
Soft FY27 guidance disappoints ResMed guided fiscal 2027 revenue to $5.75–$5.85 billion, below the $5.92 billion consensus. The shortfall, blamed on the ventilator recall and macro uncertainty like inflation in components and freight, caused a 7% share drop as investors worried about slower growth.
Guidance below expectations is a direct driver of the negative stock reaction and sets the growth outlook.
Divestiture and buybacks support focus ResMed is selling its MatrixCare software unit to Frazier Healthcare and buying Noctrix to expand into restless legs syndrome. It also raised its dividend 10% and plans over $1.85 billion in shareholder returns, including a $450 million accelerated share repurchase, signaling confidence and sharper focus on core sleep and respiratory care.
These capital actions show management's efforts to streamline and return cash, offering a positive counterweight to the margin and recall issues.

Baxter International Inc (BAX)

Q3 202629 Jul – 7 Sep 2026

▲2▼2

Baxter's Q2 beat and raised 2026 outlook lift shares, but margins stay squeezed

Q2 beat and raised guidance Baxter's second-quarter sales rose 5% to $2.96 billion and adjusted profit hit 56 cents a share, far above the 37 cents analysts expected. Management raised full-year sales and earnings guidance, a sign the core business is steadier than feared. The stock jumped sharply on the news.
This is the main new event that moved BAX and reset expectations for the year.
Debt buyback upsized Baxter increased its cash tender offer cap to $600 million, buying back several older bonds. Paying down or refinancing debt can lower interest costs and steady the balance sheet, which supports the stock by reducing financial risk.
It is a new capital-structure action that affects how investors view BAX's debt load.
Margins still under pressure Even with the upbeat quarter, adjusted gross margin fell to 38.6% and operating margin slipped to 14.2%, hurt by costly inventory, manufacturing expenses and tariffs. That means profit per sale is still shrinking, a real counterweight to the good headline numbers.
It is the main negative in the new results and explains why the beat is not purely good news.
Infusion pump hold drags on Baxter's Novum IQ large-volume pump remains under a shipment and installation hold, with customer returns and a shift to older Spectrum pumps. That is holding back Infusion Systems sales and is an execution risk that could keep a lid on growth until resolved.
It is a specific new operational risk flagged alongside the raised outlook.

August 202629 Jul – 7 Sep 2026

▲2▼2

Baxter's Q2 beat and raised 2026 outlook lift shares, but margins stay squeezed

Q2 beat and raised guidance Baxter's second-quarter sales rose 5% to $2.96 billion and adjusted profit hit 56 cents a share, far above the 37 cents analysts expected. Management raised full-year sales and earnings guidance, a sign the core business is steadier than feared. The stock jumped sharply on the news.
This is the main new event that moved BAX and reset expectations for the year.
Debt buyback upsized Baxter increased its cash tender offer cap to $600 million, buying back several older bonds. Paying down or refinancing debt can lower interest costs and steady the balance sheet, which supports the stock by reducing financial risk.
It is a new capital-structure action that affects how investors view BAX's debt load.
Margins still under pressure Even with the upbeat quarter, adjusted gross margin fell to 38.6% and operating margin slipped to 14.2%, hurt by costly inventory, manufacturing expenses and tariffs. That means profit per sale is still shrinking, a real counterweight to the good headline numbers.
It is the main negative in the new results and explains why the beat is not purely good news.
Infusion pump hold drags on Baxter's Novum IQ large-volume pump remains under a shipment and installation hold, with customer returns and a shift to older Spectrum pumps. That is holding back Infusion Systems sales and is an execution risk that could keep a lid on growth until resolved.
It is a specific new operational risk flagged alongside the raised outlook.

Latest29 Jul – 7 Sep 2026

▲2▼2

Baxter's Q2 beat and raised 2026 outlook lift shares, but margins stay squeezed

Q2 beat and raised guidance Baxter's second-quarter sales rose 5% to $2.96 billion and adjusted profit hit 56 cents a share, far above the 37 cents analysts expected. Management raised full-year sales and earnings guidance, a sign the core business is steadier than feared. The stock jumped sharply on the news.
This is the main new event that moved BAX and reset expectations for the year.
Debt buyback upsized Baxter increased its cash tender offer cap to $600 million, buying back several older bonds. Paying down or refinancing debt can lower interest costs and steady the balance sheet, which supports the stock by reducing financial risk.
It is a new capital-structure action that affects how investors view BAX's debt load.
Margins still under pressure Even with the upbeat quarter, adjusted gross margin fell to 38.6% and operating margin slipped to 14.2%, hurt by costly inventory, manufacturing expenses and tariffs. That means profit per sale is still shrinking, a real counterweight to the good headline numbers.
It is the main negative in the new results and explains why the beat is not purely good news.
Infusion pump hold drags on Baxter's Novum IQ large-volume pump remains under a shipment and installation hold, with customer returns and a shift to older Spectrum pumps. That is holding back Infusion Systems sales and is an execution risk that could keep a lid on growth until resolved.
It is a specific new operational risk flagged alongside the raised outlook.